Bionano Genomics股票今日盘中大涨5.32%。公司为一家基因组分析领域的生命科学仪器公司,主要产品为Saphyr系统,可加速诊断和寻找治疗靶点。
财报数据显示,公司最新一季度营收达6.07百万美元,虽然净利润为-44.25百万美元,但业绩较去年同期有所改善。公司产品在医疗设备行业内获得认可,使得投资者对公司未来发展前景充满信心,推动股价上涨。
机构方面,两家参与评级的券商均给予公司持有评级。分析人士认为,该公司产品具有发展潜力,加上有望获得更多订单,支撑未来业绩持续增长,构成中长线投资机会。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.